SWOG clinical trial number
S9708
Evaluation of Gemcitabine (Gemzar®) in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN).
Closed
Phase
Accrual
72%
Published
Abbreviated Title
Evaluation of Gemcitabine (Gemzar®) in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN).
Activated
12/01/1997
Closed
03/01/1999
Publication Information Expand/Collapse
2001
Evaluation of gemcitibine in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a Southwest Oncology Group Phase II study.